KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Beginning Cash Balance: 2017-2025

Historic Beginning Cash Balance for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $46.5 million.

  • Amneal Pharmaceuticals' Beginning Cash Balance rose 2.72% to $46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 54.87%. This contributed to the annual value of $91.2 million for FY2024, which is 229.84% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Beginning Cash Balance is $46.5 million, which was down 17.33% from $56.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Beginning Cash Balance high stood at $451.0 million for Q2 2021, and its period low was $28.8 million during Q1 2023.
  • Its 3-year average for Beginning Cash Balance is $76.0 million, with a median of $70.5 million in 2024.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first plummeted by 88.50% in 2023, then skyrocketed by 226.06% in 2024.
  • Amneal Pharmaceuticals' Beginning Cash Balance (Quarterly) stood at $301.7 million in 2021, then plummeted by 71.28% to $86.6 million in 2022, then increased by 1.62% to $88.0 million in 2023, then decreased by 19.95% to $70.5 million in 2024, then increased by 2.72% to $46.5 million in 2025.
  • Its last three reported values are $46.5 million in Q3 2025, $56.3 million for Q2 2025, and $109.2 million during Q1 2025.